#BEGIN_DRUGCARD DB00446

# AHFS_Codes:
08:12.08
52:04.04

# ATC_Codes:
D06AX02
D10AF03
G01AA05
J01BA01
S01AA01
S02AA01
S03AA08

# Absorption:
Rapidly and completely absorbed from gastrointestinal tract following oral administration (bioavailability 80%). Well absorbed following intramuscular administration (bioavailability 70%). Intraocular and some systemic absorption also occurs after topical application to the eye.

# Biotransformation:
Hepatic, with 90% conjugated to inactive glucuronide.

# Brand_Mixtures:
Actinac Pwr (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
Actinac Pws (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
Chlorasone (Chloramphenicol + Prednisolone Acetate)
Elase Chloromycetin Ont (Chloramphenicol + Deoxyribonuclease Pancreatic + Fibrinolysin)
Liquichlor (Chloramphenicol + Prednisolone + Squalane + Tetracaine)
Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B)
Sopamycetin/Hc Ointment (Chloramphenicol + Hydrocortisone Acetate)
Sopamycetin/Hc Ont (Chloramphenicol + Hydrocortisone Acetate)
Sopamycetin/Hc Susp (Chloramphenicol + Hydrocortisone Acetate)
Zoomycetine Spray (Chloramphenicol + Isopropyl Alcohol + Methyl Violet)

# Brand_Names:
Ak-Chlor Ophthalmic Ointment
Ak-Chlor Ophthalmic Solution
Ak-chlor
Alficetyn
Ambofen
Amphenicol
Amphicol
Amseclor
Anacetin
Aquamycetin
Austracil
Austracol
Biocetin
Biophenicol
Catilan
Chemicetin
Chemicetina
Chlomin
Chlomycol
Chlora-Tabs
Chloracol Ophthalmic Solution
Chloramex
Chloramficin
Chloramfilin
Chloramsaar
Chlorasol
Chloricol
Chlornitromycin
Chloro-25 vetag
Chlorocaps
Chlorocid
Chlorocid S
Chlorocide
Chlorocidin C
Chlorocidin C tetran
Chlorocol
Chlorofair
Chlorofair Ophthalmic Ointment
Chlorofair Ophthalmic Solution
Chloroject L
Chloromax
Chloromycetin Hydrocortisone
Chloromycetin Ophthalmic Ointment
Chloromycetin Palmitate
Chloromycetin for Ophthalmic Solution
Chloromycetny
Chloromyxin
Chloronitrin
Chloroptic
Chloroptic Ophthalmic Solution
Chloroptic S.O.P.
Chloroptic-P S.O.P.
Chlorovules
Cidocetine
Ciplamycetin
Cloramfen
Cloramficin
Cloramicol
Cloramidina
Clorocyn
Cloromisan
Clorosintex
Comycetin
Cylphenicol
Desphen
Detreomycin
Detreomycine
Dextromycetin
Doctamicina
Econochlor
Econochlor Ophthalmic Ointment
Econochlor Ophthalmic Solution
Elase-Chloromycetin
Embacetin
Emetren
Enicol
Enteromycetin
Erbaplast
Ertilen
Farmicetina
Farmitcetina
Fenicol
Fenicol Ophthalmic Ointment
Globenicol
Glorous
Halomycetin
Hortfenicol
I-Chlor Ophthalmic Solution
Intramycetin
Isicetin
Ismicetina
Isophenicol
Isopto fenicol
Juvamycetin
Kamaver
Kemicetina
Kemicetine
Klorita
Klorocid S
Leukamycin
Leukomyan
Leukomycin
Levomicetina
Levomitsetin
Levomycetin
Loromisan
Loromisin
Mastiphen
Mediamycetine
Medichol
Micloretin
Micochlorine
Micoclorina
Microcetina
Mychel
Mychel-Vet
Mycinol
Normimycin V
Novochlorocap
Novomycetin
Novophenicol
Ocu-Chlor Ophthalmic Ointment
Ocu-Chlor Ophthalmic Solution
Oftalent
Oleomycetin
Opclor
Opelor
Ophtho-Chloram Ophthalmic Solution
Ophthochlor
Ophthochlor Ophthalmic Solution
Ophthoclor
Ophthocort
Ophtochlor
Optomycin
Otachron
Otophen
Pantovernil
Paraxin
Pentamycetin
Pentamycetin Ophthalmic Ointment
Pentamycetin Ophthalmic Solution
Quemicetina
Rivomycin
Romphenil
Ronphenil
Septicol
Sificetina
Sintomicetina
Sintomicetine R
Sno-Phenicol
Sopamycetin Ophthalmic Ointment
Sopamycetin Ophthalmic Solution
Spectro-Chlor Ophthalmic Ointment
Spectro-Chlor Ophthalmic Solution
Stanomycetin
Synthomycetin
Synthomycetine
Synthomycine
Tega-Cetin
Tevcocin
Tevcosin
Tifomycin
Tifomycine
Tiromycetin
Treomicetina
Tyfomycine
Unimycetin
Veticol
Viceton

# CAS_Registry_Number:
56-75-7

# ChEBI_ID:
17698

# Chemical_Formula:
C11H12Cl2N2O5

# Chemical_IUPAC_Name:
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
798398

# Description:
An antibiotic first isolated from cultures of <i>Streptomyces venequelae</i> in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106)

# Dosage_Forms:
Liquid	Ophthalmic
Ointment	Ophthalmic
Powder, for solution	Intramuscular
Solution	Ophthalmic
Solution / drops	Ophthalmic

# Drug_Category:
Anti-Bacterial Agents
Protein Synthesis Inhibitors

# Drug_Interactions:
Acetohexamide	Chloramphenicol may increase the effect of sulfonylurea, acetohexamide.
Butalbital	Barbiturates such as butalbital may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates. Monitor for decreased serum concentrations/therapeutic effects of chloramphenicol if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. In addition, monitor for increased effects of barbiturates if chloramphenicol is initiated/dose increased, or decreased effects if chloramphenicol is discontinued/dose decreased.
Chlorpropamide	Chloramphenicol may increase the effect of sulfonylurea, chlorpropamide.
Cyclosporine	Chloramphenicol may increase the effect of cyclosporine.
Ethotoin	Increases phenytoin, modifies chloramphenicol
Fosphenytoin	Increases phenytoin, modifies chloramphenicol
Gliclazide	Chloramphenicol may increase the effect of sulfonylurea, gliclazide.
Glipizide	Chloramphenicol may increase the effect of sulfonylurea, glipizide.
Glisoxepide	Chloramphenicol may increase the effect of sulfonylurea, glisoxepide.
Glyburide	Chloramphenicol may increase the effect of sulfonylurea, glibenclamide.
Glycodiazine	Chloramphenicol may increase the effect of sulfonylurea, glycodiazine.
Lurasidone	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
Mephenytoin	Increases phenytoin, modifies chloramphenicol
Phenytoin	Increases phenytoin, modifies chloramphenicol
Rifampin	Rifampin decreases the effect of chloramphenicol
Silodosin	Chloramphenicol is a strong inhibitor of CYP3A4 may increase the serum concentration of silodosin by decreasing its metabolism thus increases the potential for adverse side effects. Combination therapy is contraindicated.
Tacrolimus	Chloramphenicol may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Chloramphenicol therapy is initiated, discontinued or altered.
Thiopental	Chloramphenicol may increase the serum concentration of Thiopental by decreasing Thiopental metabolism. Thiopental may decrease the serum concentration of Chloramphenicol by increasing Chloramphenicol metabolism. Monitor for changes in therapeutic effects of both agents if concomitant therapy is initiated, discontinued or doses are adjusted.
Tolazamide	Chloramphenicol may increase the effect of sulfonylurea, tolazamide.
Tolbutamide	Chloramphenicol may increase the effect of sulfonylurea, tolbutamide.

# Drug_Reference:
1398851	Bhutta ZA, Niazi SK, Suria A: Chloramphenicol clearance in typhoid fever: implications for therapy. Indian J Pediatr. 1992 Mar-Apr;59(2):213-9.
16039333	Nathan N, Borel T, Djibo A, Evans D, Djibo S, Corty JF, Guillerm M, Alberti KP, Pinoges L, Guerin PJ, Legros D: Ceftriaxone as effective as long-acting chloramphenicol in short-course treatment of meningococcal meningitis during epidemics: a randomised non-inferiority study. Lancet. 2005 Jul 23-29;366(9482):308-13.
1681224	Pecoul B, Varaine F, Keita M, Soga G, Djibo A, Soula G, Abdou A, Etienne J, Rey M: Long-acting chloramphenicol versus intravenous ampicillin for treatment of bacterial meningitis. Lancet. 1991 Oct 5;338(8771):862-6.
538813	Wali SS, Macfarlane JT, Weir WR, Cleland PG, Ball PA, Hassan-King M, Whittle HC, Greenwood BM: Single injection treatment of meningococcal meningitis. 2. Long-acting chloramphenicol. Trans R Soc Trop Med Hyg. 1979;73(6):698-702.
6464136	Puddicombe JB, Wali SS, Greenwood BM: A field trial of a single intramuscular injection of long-acting chloramphenicol in the treatment of meningococcal meningitis. Trans R Soc Trop Med Hyg. 1984;78(3):399-403.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
-4.69

# Experimental_LogP_Hydrophobicity:
1.14

# Experimental_Logs:
-2.11

# Experimental_Water_Solubility:
2500 mg/L (at 25 Â°C)

# Food_Interactions:
Take on an empty stomach.

# GenBank_ID:
Not Available

# Generic_Name:
Chloramphenicol

# HET_ID:
CLM

# Half_Life:
Half-life in adults with normal hepatic and renal function is 1.5 - 3.5 hours. In patients with impaired renal function half-life is 3 - 4 hours. In patients with severely impaired hepatic function half-life is 4.6 - 11.6 hours. Half-life in children 1 month to 16 years old is 3 - 6.5 hours, while half-life in infants 1 to 2 days old is 24 hours or longer and is highly variable, especially in low birth-weight infants.

# InChI_Identifier:
InChI=1S/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1

# InChI_Key:
InChIKey=WIIZWVCIJKGZOK-RKDXNWHRSA-N

# Indication:
Used in treatment of cholera, as it destroys the vibrios and decreases the diarrhea. It is effective against tetracycline-resistant vibrios. It is also used in eye drops or ointment to treat bacterial conjunctivitis.

# KEGG_Compound_ID:
C00918

# KEGG_Drug_ID:
D00104

# LIMS_Drug_ID:
446

# Mechanism_Of_Action:
Chloramphenicol is lipid-soluble, allowing it to diffuse through the bacterial cell membrane. It then reversibly binds to the L16 protein of the 50S subunit of bacterial ribosomes, where transfer of amino acids to growing peptide chains is prevented (perhaps by suppression of peptidyl transferase activity), thus inhibiting peptide bond formation and subsequent protein synthesis.

# Melting_Point:
150.5 Â°C

# Molecular_Weight_Avg:
323.129

# Molecular_Weight_Mono:
322.012326918

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
3CLA

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA448927

# Pharmacology:
Chloramphenicol is a broad-spectrum antibiotic that was derived from the bacterium Streptomyces venezuelae and is now produced synthetically. Chloramphenicol is effective against a wide variety of microorganisms, but due to serious side-effects (e.g., damage to the bone marrow, including aplastic anemia) in humans, it is usually reserved for the treatment of serious and life-threatening infections (e.g., typhoid fever). Chloramphenicol is bacteriostatic but may be bactericidal in high concentrations or when used against highly susceptible organisms. Chloramphenicol stops bacterial growth by binding to the bacterial ribosome (blocking peptidyl transferase) and inhibiting protein synthesis.

# Predicted_LogP_Hydrophobicity:
1.15

# Predicted_LogS:
-2.9

# Predicted_Water_Solubility:
4.61e-01 g/l

# Primary_Accession_No:
DB00446

# Protein_Binding:
Plasma protein binding is 50-60% in adults and 32% is premature neonates.

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic3/chloramphenicol.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00862
EXPT00942

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C(C=C1)[N+]([O-])=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
CAF
CAP
Chloramfenikol
Chloramphenicole
Chloroamphenicol
Cloroamfenicolo
D-Chloramphenicol

# Synthesis_Reference:
Not Available

# Toxicity:
Oral, mouse: LD<sub>50</sub> = 1500 mg/kg; Oral, rat: LD<sub>50</sub> = 2500 mg/kg. Toxic reactions including fatalities have occurred in the premature and newborn; the signs and symptoms associated with these reactions have been referred to as the gray syndrome. Symptoms include (in order of appearance) abdominal distension with or without emesis, progressive pallid cyanosis, vasomotor collapse frequently accompanied by irregular respiration, and death within a few hours of onset of these symptoms.

# Update_Date:
2013-02-08 16:19:21 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Chloramphenicol

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
cat

# Phase_1_Metabolizing_Enzyme_1_ID:
2417

# Phase_1_Metabolizing_Enzyme_1_Name:
Chloramphenicol acetyltransferase

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Chloramphenicol acetyltransferase
MGNYFESPFRGKLLSEQVSNPNIRVGRYSYYSGYYHGHSFDDCARYLMPDRDDVDKLVIG
SFCSIGSGAAFIMAGNQGHRAEWASTFPFHFMHEEPVFAGAVNGYQPAGDTLIGHDVWIG
TEAMFMPGVRVGHGAIIGSRALVTGDVEPYAIVGGNPARTIRKRFSDGDIQNLLEMAWWD
WPLADIEAAMPLLCTGDIPALYRHWKQRQATA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P26841

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
Not Available

# Phase_1_Metabolizing_Enzyme_2_ID:
2718

# Phase_1_Metabolizing_Enzyme_2_Name:
Chloramphenicol 3-O phosphotransferase

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Chloramphenicol 3-O phosphotransferase
MTTRMIILNGGSSAGKSGIVRCLQSVLPEPWLAFGVDSLIEAMPLKMQSAEGGIEFDADG
GVSIGPEFRALEGAWAEGVVAMARAGARIIIDDVFLGGAAAQERWRSFVGDLDVLWVGVR
CDGAVAEGRETARGDRVAGMAAKQAYVVHEGVEYDVEVDTTHKESIECAWAIAAHVVP

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
Q56148

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
cat3

# Phase_1_Metabolizing_Enzyme_3_ID:
2808

# Phase_1_Metabolizing_Enzyme_3_Name:
Chloramphenicol acetyltransferase 3

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Chloramphenicol acetyltransferase 3
MNYTKFDVKNWVRREHFEFYRHRLPCGFSLTSKIDITTLKKSLDDSAYKFYPVMIYLIAQ
AVNQFDELRMAIKDDELIVWDSVDPQFTVFHQETETFSALSCPYSSDIDQFMVNYLSVME
RYKSDTKLFPQGVTPENHLNISALPWVNFDSFNLNVANFTDYFAPIITMAKYQQEGDRLL
LPLSVQVHHAVCDGFHVARFINRLQELCNSKLK

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P00484

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_4_ID:
4118

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_5_ID:
4512

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2C9

# Phase_1_Metabolizing_Enzyme_6_ID:
4757

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2C9

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2C9
MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKV
YGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFM
KSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYID
LLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFK
KSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P11712

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP2C8

# Phase_1_Metabolizing_Enzyme_7_ID:
4924

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 2C8

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 2C8
MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKV
YGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRW
KEIRRFSLTTLRNFGMGKRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICS
VVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALT
RSYIREKVKEHQASLDVNNPRDFIDCFLIKMEQEKDNQKSEFNIENLVGTVADLFVAGTE
TTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSD
LVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNIFDPGHFLDKNGNFK
KSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLP
PSYQICFIPV

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P10632

# Phase_1_Metabolizing_Enzyme_8_Gene_Name:
CYP2C19

# Phase_1_Metabolizing_Enzyme_8_ID:
6016

# Phase_1_Metabolizing_Enzyme_8_Name:
Cytochrome P450 2C19

# Phase_1_Metabolizing_Enzyme_8_Protein_Sequence:
>Cytochrome P450 2C19
MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKI
YGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRW
KEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICS
IIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFM
ESDILEKVKEHQESMDINNPRDFIDCFLIKMEKEKQNQQSEFTIENLVITAADLLGAGTE
TTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYID
LIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDPRHFLDEGGNFK
KSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVP
PFYQLCFIPV

# Phase_1_Metabolizing_Enzyme_8_SwissProt_ID:
P33261

# Phase_1_Metabolizing_Enzyme_9_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_9_ID:
6107

# Phase_1_Metabolizing_Enzyme_9_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_9_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_9_SwissProt_ID:
P24462

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
3549294	Baxter RM, Ganoza MC, Zahid N, Chung DG: Reconstruction of peptidyltransferase activity on 50S and 70S ribosomal particles by peptide fragments of protein L16. Eur J Biochem. 1987 Mar 16;163(3):473-9.
4365366	Nierhaus D, Nierhaus KH: Identification of the chloramphenicol-binding protein in Escherichia coli ribosomes by partial reconstitution. Proc Natl Acad Sci U S A. 1973 Aug;70(8):2224-8.
7500366	Murray IA, Cann PA, Day PJ, Derrick JP, Sutcliffe MJ, Shaw WV, Leslie AG: Steroid recognition by chloramphenicol acetyltransferase: engineering and structural analysis of a high affinity fusidic acid binding site. J Mol Biol. 1995 Dec 15;254(5):993-1005.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
rplP

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7167

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
50S ribosomal protein L16

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
P0ADY7

# Drug_Target_1_SwissProt_Name:
RL16_ECOLI

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Cell projection
fimbrium

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
1670929	Swanson TN, Bilge SS, Nowicki B, Moseley SL: Molecular structure of the Dr adhesin: nucleotide sequence and mapping of receptor-binding domain by use of fusion constructs. Infect Immun. 1991 Jan;59(1):261-8.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M62834

# Drug_Target_2_GenBank_ID_Protein:
145801

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
draA

# Drug_Target_2_Gene_Sequence:
>483 bp
ATGAAAAAATTAGCGATCATGGCCGCGGCCAGCATGGTGTTCGCCGTGAGCTCCGCGCAT
GCTGGGTTCACCCCGAGTGGCACCACCGGCACCACCAAACTCACAGTTACCGAAGAGTGC
CAGGTACGGGTTGGTGACCTGACCGTGGCTAAGACTCGTGGCCAACTGACGGACGCAGCA
CCAATAGGGCCGGTCACCGTGCAAGCGCTGGGATGCGACGCCCGCCAGGTCGCGTTGAAG
GCAGACACCGATAACTTCGAACAGGGCAAGTTCTTCCTGATCAGCGACAACAATAGGGAT
AAGCTCTATGTCAATATACGGCCTACGGATAACTCCGCCTGGACGACCGACAATGGTGTC
TTCTACAAAAACGATGTCGGGAGCTGGGGTGGAATTATCGGGATCTACGTAGATGGGCAA
CAAACGAACACACCGCCCGGCAACTACACACTGACCCTGACCGGGGGTTACTGGGCAAAA
TGA

# Drug_Target_2_General_Function:
Involved in protein binding

# Drug_Target_2_General_References:
1670929	Swanson TN, Bilge SS, Nowicki B, Moseley SL: Molecular structure of the Dr adhesin: nucleotide sequence and mapping of receptor-binding domain by use of fusion constructs. Infect Immun. 1991 Jan;59(1):261-8.
1968432	Kist ML, Salit IE, Hofmann T: Purification and characterization of the Dr hemagglutinins expressed by two uropathogenic Escherichia coli strains. Infect Immun. 1990 Mar;58(3):695-702.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
2810

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
17058

# Drug_Target_2_Name:
Dr hemagglutinin structural subunit

# Drug_Target_2_Number_of_Residues:
160

# Drug_Target_2_PDB_ID:
1UT1

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF04619	Adhesin_Dr

# Drug_Target_2_Protein_Sequence:
>Dr hemagglutinin structural subunit precursor
MKKLAIMAAASMVFAVSSAHAGFTPSGTTGTTKLTVTEECQVRVGDLTVAKTRGQLTDAA
PIGPVTVQALGCDARQVALKADTDNFEQGKFFLISDNNRDKLYVNIRPTDNSAWTTDNGV
FYKNDVGSWGGIIGIYVDGQQTNTPPGNYTLTLTGGYWAK

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-21

# Drug_Target_2_Specific_Function:
Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-mannose (mannose-resistant hemagglutination (MRHA))

# Drug_Target_2_SwissProt_ID:
P24093

# Drug_Target_2_SwissProt_Name:
DRAA_ECOLX

# Drug_Target_2_Synonyms:
Dr hemagglutinin structural subunit precursor

# Drug_Target_2_Theoretical_pI:
7.25

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
GPI- anchor
Isoform 2:Cell membrane
lipid-anchor

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
15331605	Pettigrew D, Anderson KL, Billington J, Cota E, Simpson P, Urvil P, Rabuzin F, Roversi P, Nowicki B, du Merle L, Le Bouguenec C, Matthews S, Lea SM: High resolution studies of the Afa/Dr adhesin DraE and its interaction with chloramphenicol. J Biol Chem. 2004 Nov 5;279(45):46851-7. Epub 2004 Aug 24.
17376081	Korotkova N, Chattopadhyay S, Tabata TA, Beskhlebnaya V, Vigdorovich V, Kaiser BK, Strong RK, Dykhuizen DE, Sokurenko EV, Moseley SL: Selection for functional diversity drives accumulation of point mutations in Dr adhesins of Escherichia coli. Mol Microbiol. 2007 Apr;64(1):180-94.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
CD55

# Drug_Target_3_GenBank_ID_Gene:
M31516

# Drug_Target_3_GenBank_ID_Protein:
181468

# Drug_Target_3_GeneCard_ID:
CD55

# Drug_Target_3_Gene_Name:
CD55

# Drug_Target_3_Gene_Sequence:
>1146 bp
ATGACCGTCGCGCGGCCGAGCGTGCCCGCGGCGCTGCCCCTCCTCGGGGAGCTGCCCCGG
CTGCTGCTGCTGGTGCTGTTGTGCCTGCCGGCCGTGTGGGGTGACTGTGGCCTTCCCCCA
GATGTACCTAATGCCCAGCCAGCTTTGGAAGGCCGTACAAGTTTTCCCGAGGATACTGTA
ATAACGTACAAATGTGAAGAAAGCTTTGTGAAAATTCCTGGCGAGAAGGACTCAGTGATC
TGCCTTAAGGGCAGTCAATGGTCAGATATTGAAGAGTTCTGCAATCGTAGCTGCGAGGTG
CCAACAAGGCTAAATTCTGCATCCCTCAAACAGCCTTATATCACTCAGAATTATTTTCCA
GTCGGTACTGTTGTGGAATATGAGTGCCGTCCAGGTTACAGAAGAGAACCTTCTCTATCA
CCAAAACTAACTTGCCTTCAGAATTTAAAATGGTCCACAGCAGTCGAATTTTGTAAAAAG
AAATCATGCCCTAATCCGGGAGAAATACGAAATGGTCAGATTGATGTACCAGGTGGCATA
TTATTTGGTGCAACCATCTCCTTCTCATGTAACACAGGGTACAAATTATTTGGCTCGACT
TCTAGTTTTTGTCTTATTTCAGGCAGCTCTGTCCAGTGGAGTGACCCGTTGCCAGAGTGC
AGAGAAATTTATTGTCCAGCACCACCACAAATTGACAATGGAATAATTCAAGGGGAACGT
GACCATTATGGATATAGACAGTCTGTAACGTATGCATGTAATAAAGGATTCACCATGATT
GGAGAGCACTCTATTTATTGTACTGTGAATAATGATGAAGGAGAGTGGAGTGGCCCACCA
CCTGAATGCAGAGGAAAATCTCTAACTTCCAAGGTCCCACCAACAGTTCAGAAACCTACC
ACAGTAAATGTTCCAACTACAGAAGTCTCACCAACTTCTCAGAAAACCACCACAAAAACC
ACCACACCAAATGCTCAAGCAACACGGAGTACACCTGTTTCCAGGACAACCAAGCATTTT
CATGAAACAACCCCAAATAAAGGAAGTGGAACCACTTCAGGTACTACCCGTCTTCTATCT
GGGCACACGTGTTTCACGTTGACAGGTTTGCTTGGGACGCTAGTAACCATGGGCTTGCTG
ACTTAG

# Drug_Target_3_General_Function:
Not Available

# Drug_Target_3_General_References:
12672958	Uhrinova S, Lin F, Ball G, Bromek K, Uhrin D, Medof ME, Barlow PN: Solution structure of a functionally active fragment of decay-accelerating factor. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4718-23. Epub 2003 Apr 2.
12675719	Storry JR, Sausais L, Hue-Roye K, Mudiwa F, Ferrer Z, Blajchman MA, Lublin DM, Ma BW, Miquel JF, Nervi F, Pereira J, Reid ME: GUTI: a new antigen in the Cromer blood group system. Transfusion. 2003 Mar;43(3):340-4.
1377029	Nakano Y, Sumida K, Kikuta N, Miura NH, Tobe T, Tomita M: Complete determination of disulfide bonds localized within the short consensus repeat units of decay accelerating factor (CD55 antigen). Biochim Biophys Acta. 1992 Jun 12;1116(3):235-40.
1711208	Ewulonu UK, Ravi L, Medof ME: Characterization of the decay-accelerating factor gene promoter region. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4675-9.
1712233	Nakano Y, Sugita Y, Ishikawa Y, Choi NH, Tobe T, Tomita M: Isolation of two forms of decay-accelerating factor (DAF) from human urine. Biochim Biophys Acta. 1991 Jul 8;1074(2):326-30.
1720702	Reid ME, Mallinson G, Sim RB, Poole J, Pausch V, Merry AH, Liew YW, Tanner MJ: Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency). Blood. 1991 Dec 15;78(12):3291-7.
1824699	Moran P, Raab H, Kohr WJ, Caras IW: Glycophospholipid membrane anchor attachment. Molecular analysis of the cleavage/attachment site. J Biol Chem. 1991 Jan 15;266(2):1250-7.
2428813	Sugita Y, Negoro T, Matsuda T, Sakamoto T, Tomita M: Improved method for the isolation and preliminary characterization of human DAF (decay-accelerating factor). J Biochem (Tokyo). 1986 Jul;100(1):143-50.
2433596	Caras IW, Davitz MA, Rhee L, Weddell G, Martin DW Jr, Nussenzweig V: Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature. 1987 Feb 5-11;325(6104):545-9.
2436222	Medof ME, Lublin DM, Holers VM, Ayers DJ, Getty RR, Leykam JF, Atkinson JP, Tykocinski ML: Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2007-11.
7519480	Lublin DM, Mallinson G, Poole J, Reid ME, Thompson ES, Ferdman BR, Telen MJ, Anstee DJ, Tanner MJ: Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes. Blood. 1994 Aug 15;84(4):1276-82.
7525274	Ward T, Pipkin PA, Clarkson NA, Stone DM, Minor PD, Almond JW: Decay-accelerating factor CD55 is identified as the receptor for echovirus 7 using CELICS, a rapid immuno-focal cloning method. EMBO J. 1994 Nov 1;13(21):5070-4.

# Drug_Target_3_HGNC_ID:
HGNC:2665

# Drug_Target_3_HPRD_ID:
00500

# Drug_Target_3_ID:
1196

# Drug_Target_3_Locus:
1q32

# Drug_Target_3_Molecular_Weight:
41400

# Drug_Target_3_Name:
Complement decay-accelerating factor

# Drug_Target_3_Number_of_Residues:
381

# Drug_Target_3_PDB_ID:
1OK9

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF00084	Sushi

# Drug_Target_3_Protein_Sequence:
>Complement decay-accelerating factor precursor
MTVARPSVPAALPLLGELPRLLLLVLLCLPAVWGDCGLPPDVPNAQPALEGRTSFPEDTV
ITYKCEESFVKIPGEKDSVICLKGSQWSDIEEFCNRSCEVPTRLNSASLKQPYITQNYFP
VGTVVEYECRPGYRREPSLSPKLTCLQNLKWSTAVEFCKKKSCPNPGEIRNGQIDVPGGI
LFGATISFSCNTGYKLFGSTSSFCLISGSSVQWSDPLPECREIYCPAPPQIDNGIIQGER
DHYGYRQSVTYACNKGFTMIGEHSIYCTVNNDEGEWSGPPPECRGKSLTSKVPPTVQKPT
TVNVPTTEVSPTSQKTTTKTTTPNAQATRSTPVSRTTKHFHETTPNKGSGTTSGTTRLLS
GHTCFTLTGLLGTLVTMGLLT

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
1-34

# Drug_Target_3_Specific_Function:
Also acts as the receptor for echovirus 7 and related viruses (echoviruses 13, 21, 29 and 33)

# Drug_Target_3_SwissProt_ID:
P08174

# Drug_Target_3_SwissProt_Name:
DAF_HUMAN

# Drug_Target_3_Synonyms:
CD55 antigen
Complement decay-accelerating factor precursor

# Drug_Target_3_Theoretical_pI:
7.64

# Drug_Target_3_Transmembrane_Regions:
None

#END_DRUGCARD DB00446
